Login / Signup

4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.

Karolina I WoronieckaKristen E RhodinCosette DechantXiuyu CuiPakawat ChongsathidkietDaniel WilkinsonJessica Waibl-PolaniaLuis Sanchez-PerezPeter E Fecci
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Although poor T-cell activation and severe T-cell exhaustion appear to be limiting factors for checkpoint blockade in GBM, 4-1BB agonism obviates these limitations and produces long-term survival when combined with anti-PD-1 therapy. Furthermore, this combination therapy is limited by TIL 4-1BB expression, but not by the intracranial compartment, and therefore may be particularly well-suited to GBM.
Keyphrases
  • combination therapy
  • growth factor
  • recombinant human
  • poor prognosis
  • dna damage
  • optic nerve
  • cell cycle
  • binding protein
  • stem cells
  • long non coding rna
  • bone marrow
  • oxidative stress
  • smoking cessation